Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.therap.2020.10.004 http://scihub22266oqcxt.onion/10.1016/j.therap.2020.10.004 34238584!7603945!34238584     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Therapie 2021 ; 76 (4): 335-345 Nephropedia Template TP {{tp|p=34238584|t=2021. Harnessing immunotherapy to combat COVID-19: A modern snake oil or silver bullet?|pdf=|usr=}}{{34238584}} gab.com Text Harnessing immunotherapy to combat COVID-19: A modern snake oil or silver bullet JO: Therapie http://www.kidney.de/pget.php?&tw=1&pmid=34238584 #FOAvip Coronavirus disease 2019 (COVID-19), an infectious disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2), has emerged into a global health and economic menace. Amidst the COVID-19 turmoil, recent failures/uncertain outcomes in clinical trials involving the anti-malarial (hydroxychloroquine), anti-viral (remdesivir) or the combination of anti-malarial/antibiotic (hydroxychloroquine/azithromycin) regimens have predisposed the physicians to distrust these "highly-touted" drugs for COVID-19. In this milieu, immunotherapy might be a credible modality to target or modify specific/non-specific immune responses that interfere with the survival of intracellular pathogens. This scientific review throws light on the epidemiology of COVID-19, its pathogenesis and the current clinical scenario of immunotherapeutics including convalescent plasma (CP), type-1 interferons (IFN-I) and human monoclonal antibodies (mAbs) to combat COVID-19. The treatment outcomes underscore that immunotherapy might be a reliable tool to assuage COVID-19-associated immunopathology. However, specific patient pool studies are warranted to ascertain the precise (re)purposing of immunotherapeutics for COVID-19. Twit Text FOAVip Harnessing immunotherapy to combat COVID-19: A modern snake oil or silver bullet ????Therapie http://www.kidney.de/pget.php?&tw=1&pmid=34238584 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34238584 #FOAvip English Wikipedia <ref>{{Cite pmid|34238584}}</ref> Harnessing immunotherapy to combat COVID-19: A modern snake oil or silver bullet? #MMPMID34238584 Gunjegaonkar SM; Shanmugarajan TS; Arunsundar M; Arjun UVNV; Devi K; Wankhede SB; Ravichandiran V Therapie 2021[Jul]; 76 (4): 335-345 PMID34238584show ga Coronavirus disease 2019 (COVID-19), an infectious disease caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2), has emerged into a global health and economic menace. Amidst the COVID-19 turmoil, recent failures/uncertain outcomes in clinical trials involving the anti-malarial (hydroxychloroquine), anti-viral (remdesivir) or the combination of anti-malarial/antibiotic (hydroxychloroquine/azithromycin) regimens have predisposed the physicians to distrust these "highly-touted" drugs for COVID-19. In this milieu, immunotherapy might be a credible modality to target or modify specific/non-specific immune responses that interfere with the survival of intracellular pathogens. This scientific review throws light on the epidemiology of COVID-19, its pathogenesis and the current clinical scenario of immunotherapeutics including convalescent plasma (CP), type-1 interferons (IFN-I) and human monoclonal antibodies (mAbs) to combat COVID-19. The treatment outcomes underscore that immunotherapy might be a reliable tool to assuage COVID-19-associated immunopathology. However, specific patient pool studies are warranted to ascertain the precise (re)purposing of immunotherapeutics for COVID-19. |*Immunotherapy[MESH] |Antibodies, Monoclonal/therapeutic use[MESH] |Antiviral Agents/therapeutic use[MESH] |COVID-19 Serotherapy[MESH] |COVID-19/*immunology/*therapy/virology[MESH] |Humans[MESH] |Immunization, Passive[MESH] |Interferon Type I/therapeutic use[MESH] |SARS-CoV-2/immunology[MESH]Harnessing immunotherapy to combat COVID-19: A modern snake oil or sil(epmc).pdf DeepDyve Pubget Overpricing